Evidence map›Paper›PMID 24967549›Full record

ArticleColloids and surfaces. B, Biointerfaces2014

Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells.

Siu Ling Leung, Zhengbao Zha, Celine Cohn, Zhifei Dai, Xiaoyi Wu

Open access · greenAbstract read
In one paragraph

Article in Colloids and surfaces. B, Biointerfaces, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Advancing the Pharmaceutical Potential of Bioinorganic Hybrid Lipid-Based Assemblies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Siu Ling LeungDepartment of Aerospace and Mechanical Engineering, the University of Arizona, Tucson, AZ 85721, USA.
Zhengbao ZhaDepartment of Aerospace and Mechanical Engineering, the University of Arizona, Tucson, AZ 85721, USA; Department of Biomedical Engineering, College of Engineering, Peking University, Beijing 100871, People's Republic of China.
Celine CohnBiomedical Engineering and Bio5 Institute, The University of Arizona, Tucson, AZ 85721, USA.
Zhifei DaiDepartment of Biomedical Engineering, College of Engineering, Peking University, Beijing 100871, People's Republic of China.
Xiaoyi WuDepartment of Aerospace and Mechanical Engineering, the University of Arizona, Tucson, AZ 85721, USA; Biomedical Engineering and Bio5 Institute, The University of Arizona, Tucson, AZ 85721, USA. Electronic address: xwu@arizona.edu.
University of Arizona · USPeking University · CN

Funding

Cardiovascular Biomedical Engineering Training GrantT32HL007955 · NHLBI · UNIVERSITY OF ARIZONA · PI BARTON, JENNIFER KEHLET · 2001 to 2020
$5.1M
Protein-cell assemblies as tissue-mimicsR21EB009160 · NIBIB · UNIVERSITY OF ARIZONA · PI WU, XIAOYI · 2009 to 2010
$409k
NHLBI NIH HHS T32 HL007955NIBIB NIH HHS R21 EB009160NIBIB NIH HHS R21EB009160
6 · The paper itself

Abstract

Chemical conjugation of anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs) to organic-inorganic hybrid liposomal immunocerasomes via maleimide-thiol coupling chemistry is explored as a mechanism for selectively targeting cancer cells. The cellular uptake and internalization of immunocerasomes are investigated in A431 cells that express an abnormally high level of EGFR, DU145 cells that overexpress EGFR, and HL-60 cells that are used as a negative control. The internalization study reveals a strong correlation between the receptor-mediated endocytosis of immunocerasomes and the membrane expression of EGFR. Further, free anti-EGFR mAbs and immunocerasomes conjugated with anti-EGFR mAbs at nanomolar doses display similar anti-proliferative effects on A431 cells. Additionally, serum proteins greatly reduce the cellular uptake of cerasomes that is mediated by non-specific receptors, but have no adverse effects on the specific EGFR-mediated delivery of immunocerasomes to A431 cells.

Indexed as

Antibodies, MonoclonalCell Line, TumorCell ProliferationEndocytosisErbB ReceptorsHumansInorganic ChemicalsLipidsNanoparticlesOrganic ChemicalsSpectrometry, FluorescenceUnilamellar LiposomesAntibodies, MonoclonalErbB ReceptorsInorganic ChemicalsLipidsOrganic ChemicalsUnilamellar LiposomesAnti-EGFR antibodyCancer cellsOrganic–inorganic hybrid lipid nanovesiclesSelective targeting

Identifiers

PMID24967549
PMCPMC7038778
OpenAlexW1991500693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.